Taxol (paclitaxel) and related taxane drugs are widely used chemotherapies against solid tumor types in adults. However, taxanes do not generally enter the brain and so they... | [more]
Welcome to Dana-Farber/Harvard Cancer Center
Dana-Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer center in the world, bringing together the cancer research efforts of our seven member institutions: Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.Funded by a grant from the National Cancer Institute, we have joined these seven renowned Harvard-affiliated medical centers into one collective force dedicated to the fight against cancer. Based in Boston, DF/HCC consists of more than 1,000 researchers with a singular goal -- to find new and innovative ways to combat cancer.
Announcements
- Seminars in Oncology: "The Many Faces of Li Fraumeni Syndrome: p53" Posted: 05-15-13
- Limited Time: 20-40% Discount on Selected Affymetrix GeneChip Arrays Posted: 05-15-13
- Seminars in Oncology: 2013 SWERLING LECTURES Posted: 05-08-13
Latest Cancer News
Taking Cabazitaxel into Childhood Cancers
Afatinib with Post-Operative Radiation in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the United States. These cancers are usually treated with either surgery or radiation, and... | [more]
Visualizing the Birth of Cancer in Zebrafish
Cancer behaves differently in living animals than it does in a dish, so designing animal models is integral to both basic and clinical research in the DF/HCC Cancer Genetics... | [more]
